US 12,070,465 B2
Compositions and methods for the prevention and treatment of hearing loss
Jian Zuo, Omaha, NE (US); Jeff North, Omaha, NE (US); Santanu Hati, Omaha, NE (US); and Marisa Laura Zallocchi, Omaha, NE (US)
Assigned to Ting Therapeutics LLC, Omaha, NE (US)
Appl. No. 18/031,998
Filed by Ting Therapeutics LLC, Omaha, NE (US)
PCT Filed Sep. 15, 2021, PCT No. PCT/US2021/050425
§ 371(c)(1), (2) Date Apr. 14, 2023,
PCT Pub. No. WO2022/060811, PCT Pub. Date Mar. 24, 2022.
Claims priority of provisional application 63/078,571, filed on Sep. 15, 2020.
Prior Publication US 2023/0330097 A1, Oct. 19, 2023
Int. Cl. A61K 31/55 (2006.01); A61K 31/397 (2006.01); A61K 31/45 (2006.01); A61P 27/16 (2006.01)
CPC A61K 31/55 (2013.01) [A61K 31/397 (2013.01); A61K 31/45 (2013.01); A61P 27/16 (2018.01)] 12 Claims
OG exemplary drawing
 
1. A method to prevent or treat hearing loss caused by excitotoxic damage comprising: administering to an animal or human in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is a derivative of Piperlongumine, wherein the Piperlongumine derivative is selected from a group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry